Paris La Défense, FRANCE, March 12th, 2024 – At the end of January, SGD Pharma, a global leader in glass primary packaging for the pharmaceutical industry, started a two-week trial using 100% hydrogen burners for industrial-scale glass production. The trial, conducted at SGD Pharma’s state-of-the-art Saint-Quentin-Lamotte (SQLM) manufacturing plant in France, was a resounding success and will inform SGD Pharma’s decarbonization roadmap which aims to reduce CO2 emissions from 2020 by 35% in 2030 and by 65% in 2040.
During the trial, up to 50% of the burners at SQLM were converted to operate using a combination of hydrogen and oxygen combustion instead of the previously used Oxygas. The hydrogen burners contributed around 75% of the total volume of combustion gases. Air Liquide supported SGD Pharma during the trials by the provision of equipment and hydrogen as well as technical assistance and expertise. The outstanding results of the trial confirm the possibility of using hydrogen to decarbonate the combustion of our furnaces.
SGD Pharma intends to lead the decarbonization of the glass pharma industry and this step is just the latest on its ambitious roadmap. CEO Olivier Rousseau explains: “We have been working with the Science Based Targets initiative (SBTi) on the reduction of CO2 emissions across our five glass manufacturing plants (including SQLM in France, our two other EU plants, and both our Indian and Chinese plants) and have developed a 1.5°C decarbonization pathway and target validation. As part of the plan, we are currently rebuilding one of the furnaces at SQLM which will increase electricity output of the furnace by 40%. The trialed hydrogen burners will help us to achieve our SBTi targets and to continue with the investment in our SQLM plant which is the world’s most advanced pharma-grade glass manufacturing plant, as well as upgrading our other sites across multiple geographies.”
For more information on SGD Pharma’s CSR commitments, visit the SGD Pharma website: https://www.sgd-pharma.com
12.03.2024, SGD Pharma
News material on the Site is copyright and belongs to the Company or to its third party news provider, and all rights are reserved. Any User who accesses such material may do so only for its own personal use, and the use of such material is at the sole risk of the User. Redistribution or other commercial exploitation of such news material is expressly prohibited. Where such news material is provided by a third party, each User agrees to observe and be bound by the specific terms of use applying to such news material. We do not represent or endorse the accuracy or reliability of any of the info contained in any news or external websites referred to in the news.
Should the content or the design of these sites violate third parties rights or legal prescriptions, we kindly ask you to send us a respective message without invoice or cost. We guarantee that passages where the claim is considered as justified will be removed immediately, without any necessity to involve any lawyer into this issue. We will reject any claim caused by submission of a honorary note in this regard without any prior contact and confirmation of the issueby us and we reserve the right ssue counter claim ourselves because of violation of aforesaid conditions.